Edition:
United States

Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

4.28USD
14 Dec 2017
Change (% chg)

$-0.18 (-4.04%)
Prev Close
$4.46
Open
$4.43
Day's High
$4.48
Day's Low
$4.26
Volume
1,325,772
Avg. Vol
1,184,155
52-wk High
$9.86
52-wk Low
$4.20

Latest Key Developments (Source: Significant Developments)

Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY.INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 "PROOF-OF-CONCEPT" STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA.  Full Article

Inovio pharmaceuticals reports 2017 third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals reports 2017 third quarter financial results.Q3 loss per share $0.39.Q3 revenue $2.6 million versus $12.5 million.Q3 revenue view $9.4 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Inovio Pharmaceuticals - ‍as of Sept 30, 2017, cash and cash equivalents and short-term investments were $141.9 million versus $104.8 million as of Dec 31, 2016​.  Full Article

Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14
Thursday, 2 Nov 2017 06:23am EDT 

Nov 2 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14.Inovio Pharmaceuticals - Approval ‍included amendment to the $35 million payment co to receive from Apollobio as per agreement agreed between co, Apollobio.Inovio Pharmaceuticals says amendment was to reduce the purchase price of the $35 million payment from $8.20 to $7.22 per share - SEC Filing​.  Full Article

Inovio Pharmaceuticals qtrly loss per share $0.35
Wednesday, 15 Mar 2017 04:05pm EDT 

Inovio Pharmaceuticals Inc : Inovio pharmaceuticals reports 2016 fourth quarter and year end financial results . Q4 revenue $8.5 million . Qtrly loss per share $0.35 .Q4 revenue view $5.9 million -- Thomson Reuters I/B/E/S.  Full Article

Inovio, Apollobio to develop and commercialize hpv pre-cancer immunotherapy VGX-3100 in Greater China
Monday, 13 Feb 2017 06:00am EST 

Inovio Pharmaceuticals Inc : Inovio and Apollobio to collaborate on development and commercialization of hpv pre-cancer immunotherapy VGX-3100 in Greater China . Inovio Pharmaceuticals Inc - Inovio will receive $15 million in upfront and near term payments comprising an initial $3 million signing fee . Inovio Pharmaceuticals Inc - Inovio will receive a $12 million milestone upon lifting of VGX-3100 Phase 3 pre-initiation clinical hold by FDA . Inovio Pharmaceuticals Inc - under a separate equity agreement, Apollobio will invest in Inovio common stock subsequent to lifting of clinical hold . Inovio Pharmaceuticals Inc - aggregate investment, which is expected to be completed in first half of 2017, will not exceed $35 million . Inovio Pharmaceuticals Inc - Apollobio will fund all clinical development costs within licensed territory, and will pay Inovio up to $20 million . Inovio Pharma- agreements are subject to People's Republic of China corporate and regulatory approvals, payments are subject to PRC currency approvals .Inovio - payment of $20 million based upon achievement of certain regulatory milestones in U.S., China, Korea, double digit royalties on net sales of VGX-3100.  Full Article

Inovio launches Zika vaccine trial
Monday, 29 Aug 2016 07:00am EDT 

Inovio Pharmaceuticals Inc : Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy . Expects to report results before end of this year .Is developing its Zika vaccine, GLS-5700, with Geneone Life Science, Inc. And academic collaborators from US and Canada.  Full Article

Inovio Pharmaceuticals Q2 loss per share $0.26
Monday, 8 Aug 2016 08:00am EDT 

Inovio Pharmaceuticals Inc : Inovio Pharmaceuticals reports 2016 second quarter financial results . Q2 revenue $6.2 million versus $5.3 million . Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.26 .Q2 revenue view $5 million -- Thomson Reuters I/B/E/S.  Full Article

Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial
Tuesday, 26 Jul 2016 10:28am EDT 

Inovio Pharmaceuticals Inc: Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial . Center phase I trial to evaluate inovio's Zika dna vaccine . Says expect to complete subject dosing and report interim phase I results later this year .Health Canada's Health Products and Food Branch has also approved co's Zika study.  Full Article

Inovio, Geneone Life Science get approval to test Zika vaccine on humans
Monday, 20 Jun 2016 07:00am EDT 

Inovio Pharmaceuticals : Inovio Pharmaceuticals and Geneone Life Science have received approval to initiate a phase i human trial to evaluate it's Zika DNA vaccine .Inovio Pharmaceuticals And Geneone Life Science Receive Approval For First In-Man Zika vaccine clinical trial.  Full Article

Inovio Pharmaceuticals says stock offering of up to $50 mln - SEC Filing
Friday, 17 Jun 2016 05:00pm EDT 

Inovio Pharmaceuticals Inc :May offer and sell shares of common stock having aggregate offering price of up to $50 million through Stifel as sales agent.  Full Article

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* ‍INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL​ Source text for Eikon: Further company coverage: